Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 193

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Toward theragnostics

Pene, Frédéric, Courtine, Emilie, Cariou, Alain, Mira, Jean-Paul · 2009 · Critical Care Medicine

Abstract

Theragnostics is a treatment strategy that combines therapeutics with diagnostics. It associates both a diagnostic test that identifies patients most likely to be helped or harmed by a new medication, and targeted drug therapy based on the test results. Bioinformatics, genomics, proteomics, and functional genomics are molecular biology tools essential for the progress of molecular theragnostics. These tools generate the genetic and protein information required for the development of diagnostic assays. Theragnostics includes a wide range of subjects, including personalized medicine, pharmacogenomics, and molecular imaging to develop efficient new targeted therapies with adequate benefit/risk to patients and a better molecular understanding of how to optimize drug selection. Furthermore, theragnostics aims to monitor the response to the treatment, to increase drug efficacy and safety. In addition, theragnostics could eliminate the unnecessary treatment of patients for whom therapy is not appropriate, resulting in significant drug cost savings for the healthcare system. However, the introduction of theragnostic tests into routine health care requires both a demonstration of cost-effectiveness and the availability of appropriate accessible testing systems. This review reports validation studies in oncology and infectious diseases that have demonstrated the benefits of such approach in well-defined subpopulations of patients, moving the field from the drug development process toward clinical practice and routine application. Theragnostics may change the usual business model of pharmaceutical companies from the classic blockbuster model toward targeted therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/ccm.0b013e3181921349

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 41

  1. Wilson, 2007, Clin Pharmacol Ther, 81, 153, 10.1038/sj.clpt.6100088 · DOI
  2. Ozdemir, 2006, Nat Biotechnol, 24, 942, 10.1038/nbt0806-942 · DOI
  3. Dawood, 2008, Semin Oncol, 35, 64, 10.1053/j.seminoncol.2007.11.012 · DOI
  4. Revillion, 2008, Ann Oncol, 19, 73, 10.1093/annonc/mdm431 · DOI
  5. Olver, 2008, Future Oncol, 4, 125, 10.2217/14796694.4.1.125 · doi:10.2217/14796694.4.1.125
  6. Jabbour, 2008, Expert Rev Anticancer Ther, 8, 99, 10.1586/14737140.8.1.99 · DOI
  7. Wheatley-Price, 2008, Curr Opin Oncol, 20, 162, 10.1097/CCO.0b013e3282f335a3 · DOI
  8. Eberhard, 2008, J Clin Oncol, 26, 983, 10.1200/JCO.2007.12.9858 · DOI · Paper page
  9. Lander, 2001, Nature, 409, 860, 10.1038/35057062 · DOI · Paper page
  10. Craddock, 2007, Clin Med, 7, 632, 10.7861/clinmedicine.7-6-632 · doi:10.7861/clinmedicine.7-6-632
  11. de Kogel, 2007, Oncologist, 12, 1390, 10.1634/theoncologist.12-12-1390 · doi:10.1634/theoncologist.12-12-1390
  12. Fatouros, 2008, Ann Surg Oncol, 15, 21, 10.1245/s10434-007-9612-4 · DOI
  13. Roukos, 2007, Nat Clin Pract Oncol, 4, 578, 10.1038/ncponc0930 · DOI
  14. Calin, 2006, Nat Rev Cancer, 6, 857, 10.1038/nrc1997 · DOI · Paper page
  15. Sears, 2007, Adv Cancer Res, 96, 51, 10.1016/S0065-230X(06)96003-5 · DOI
  16. Reis-Filho, 2006, J Clin Pathol, 59, 225, 10.1136/jcp.2005.028324 · DOI
  17. Blenkiron, 2007, Hum Mol Genet, 16, R106, 10.1093/hmg/ddm056 · DOI · Paper page
  18. Schetter, 2008, JAMA, 299, 425
  19. Cooper, 2004, BMJ, 329, 533, 10.1136/bmj.329.7465.533 · DOI · Paper page
  20. Huletsky, 2005, Clin Infect Dis, 40, 976, 10.1086/428579 · doi:10.1086/428579
  21. van Hal, 2007, J Clin Microbiol, 45, 2486, 10.1128/JCM.00139-07 · DOI
  22. Cunningham, 2007, J Hosp Infect, 65, 24, 10.1016/j.jhin.2006.09.019 · doi:10.1016/j.jhin.2006.09.019
  23. Jones, 2007, Top HIV Med, 15, 48
  24. Mueller, 2007, Eur J Med Res, 12, 441
  25. Phillips, 2001, JAMA, 286, 2270, 10.1001/jama.286.18.2270 · DOI · Paper page
  26. Moore, 2007, Arch Intern Med, 167, 1752, 10.1001/archinte.167.16.1752 · DOI · Paper page
  27. Evans, 2004, Nature, 429, 464, 10.1038/nature02626 · DOI · Paper page
  28. Yin, 2007, Thromb Res, 120, 1, 10.1016/j.thromres.2006.10.021 · DOI · Paper page
  29. Flockhart, 2008, Genet Med, 10, 139, 10.1097/GIM.0b013e318163c35f · DOI · Paper page
  30. Anderson, 2007, Circulation, 116, 2563, 10.1161/CIRCULATIONAHA.107.737312 · DOI · Paper page
  31. Caraco, 2008, Clin Pharmacol Ther, 83, 460, 10.1038/sj.clpt.6100316 · DOI · Paper page
  32. Ando, 2007, Curr Opin Mol Ther, 9, 258
  33. Maitland, 2006, Trends Pharmacol Sci, 27, 432, 10.1016/j.tips.2006.06.007 · DOI
  34. Dumaual, 2007, Pharmacogenomics, 8, 293, 10.2217/14622416.8.3.293 · DOI
  35. Mallal, 2008, N Engl J Med, 358, 568, 10.1056/NEJMoa0706135 · DOI · Paper page
  36. Phillips, 2007, Curr Opin Allergy Clin Immunol, 7, 324, 10.1097/ACI.0b013e32825ea68a · DOI
  37. Yu, 2007, Expert Rev Mol Diagn, 7, 659, 10.1586/14737159.7.5.659 · DOI
  38. Facey, 2007, Health Technol Assess, 11, iii, 10.3310/hta11440 · DOI · Paper page
  39. Goldstein, 2005, Oncology, 69, 326, 10.1159/000089765 · doi:10.1159/000089765
  40. Avril, 2007, Future Oncol, 3, 215, 10.2217/14796694.3.2.215 · DOI
  41. Loprevite, 2007, Clin Cancer Res, 13, 6518, 10.1158/1078-0432.CCR-07-0805 · DOI

Cited by

See all 193

Metadata

Authors
Pene, F., Courtine, E., Cariou, A., & Mira, J.-P.
Venue
Critical Care Medicine
Published
2009-01
Volume
37
Issue
Supplement
Pages
S50-S58
ISSN
0090-3493 (ISSN-L)
OpenAlex
W4256007139
Cited by
193
References
1
FWCI
8.55
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Toward theragnostics. https://app.cochat.ai/papers/10.1097/ccm.0b013e3181921349
The paper
Pene, F., Courtine, E., Cariou, A., & Mira, J.-P. (2009). Toward theragnostics. Critical Care Medicine. https://doi.org/10.1097/ccm.0b013e3181921349

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.